Date: 2014-05-02
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Mateon Therapeutics (USA - CA)
Product: CA4P (fosbretabulin tromethamine)
Action
mechanism: vascular disrupting agent/mitotic inhibitor/tubulin binder. CA4P (combretastatin-A4 phosphate or fosbretabulin) is an investigational vascular disrupting agent (VDA) product candidate, Upon administration, fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which targets and binds to tubulin dimers and prevents microtubule polymerization, thereby resulting in mitotic arrest and apoptosis in endothelial cells. It also disrupts the engagement of the endothelial cell–specific junctional molecule vascular endothelial-cadherin (VE-cadherin) and so the activity of the VE-cadherin/?-catenin/Akt signaling pathway, which may result in the inhibition of endothelial cell migration and capillary tube formation. As a result of fosbretabulin's dual mechanism of action, the tumor vasculature collapses, resulting in reduced tumor blood flow and ischemic necrosis of tumor tissue.
Disease: PNET or GI-NET neuroendocrine tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: GI-NETorPNET is a phase 2 study to investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic PNETs or GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy. (NCT02132468)
Latest
news: * On May 2, 2014, a Phase 2 trial sponsored by Mateon Therapeutics was published on the NIH website ClinicalTrials.gov for fosbretabulin tromethamine and is currently recruiting participants.
